Trial Profile
An Open-label, Multiple-dose Study Of The Absorption And Systemic Pharmacokinetics Of An2690 Applied As A 7.5% Solution To All Toenails Of Adult Patients With Moderate To Severe Onychomycosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2018
Price :
$35
*
At a glance
- Drugs Tavaborole (Primary)
- Indications Onychomycosis
- Focus Pharmacokinetics
- Acronyms ADME II
- Sponsors Anacor Pharmaceuticals
- 20 May 2014 New trial record